Drugs targeting the VEGF–VEGFR pathway, such as Vatalanib, Sunitinib, and Cediranib found therapeutic application in the treatment of many hypervascular solid tumors including GBM [23,24,25,26,27,28]. The gene discussed is KDR; the disease is glioblastoma.